Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab versus best supportive care after adjuvant cisplatin-based chemotherapy in resected NSCLC
NL-OMON54656Phase 3Recruiting
- Sponsor
- Roche
- Start
- Apr 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Atezolizumab with Best supportive care (2 arms). Primary endpoint: Disease-free survival. Started Apr 2017; status: recruiting.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON54656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54656.